Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies.

Falanga A, Rickles FR.

Hematology Am Soc Hematol Educ Program. 2007:165-71.

Heparin in tumor progression and metastatic dissemination.

Falanga A, Marchetti M.

Semin Thromb Hemost. 2007;33(7):688-94.

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.

Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T.

Exp Hematol. 2007 Sep;35(9):1476.

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW; American Society of Clinical Oncology.

J Clin Oncol. 2007;25(34):5490-505.